SIGA Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $218.4M
- Price
- $3.04
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.36%
- Volume
- 1.5M
About
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Quick stats
Shares outstanding71.8M
Computed float40.6M
Float / shares56.5%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001010086
Websitehttps://www.siga.com
AI Summary
AI-generated1/8
majorbearishearnings
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
SIGA reported Q2 2026 revenue of $41.0 million and diluted EPS of $0.17, reflecting a roughly 50% decline compared to the prior year.
The decrease follows the completion of the final procurement order under the 19C BARDA contract, though the company delivered $37 million of TPOXX to US and international customers.
During the quarter, the company paid a special dividend of $0.60 per share and generated $12.5 million in net income.
Red flags
- Q2 revenue and net income declined approximately 50% year-over-year
- Final procurement order under the 19C BARDA contract completed; renewal status not disclosed